D-serine Serum Levels in Schizophrenia: Relation to Psychopathology

Czech version

Authors: J. Hons ¹; R. Žirko ¹; M. Ulrychová ²; E. Čermáková ³; J. Libiger ¹
Authors‘ workplace: Psychiatrická klinika, LF UK a FN, Hradec Králové ; přednosta prof. MUDr. J. Libiger, CSc. Ústav klinické biochemie a diagnostiky, FN, Hradec Králové ¹; přednosta prof. MUDr. V. Palička, CSc. Ústav lékařské biofyziky LF UK, Hradec Králové ²; přednosta doc. Ing. J. Hanuš, CSc. ³
Published in: Čes. a slov. Psychiat., 104, 2008, No. 6, pp. 281-288.
Category: Original Article

Overview

The hypofunction of glutamatergic NMDA (N-methyl-D-aspartate) receptor is involved in pathophysiology of schizophrenia. Amino acid D-serine acts as endogenous co-agonist at the glycine modulatory site of the NMDA receptor. Significantly decreased D-serine serum levels were reported in patients with schizophrenia in comparison to healthy control subjects. Positive clinical effect of peripherally administered D-serine was demonstrated. D-serine improved positive and negative symptoms in patients with schizophrenia treated with first and second generation antipsychotics in the clinical studies. We did not find any significant association between D-serine serum level and the PANSS (The Positive and Negative Syndrome Scale) and the SANS (The Scale for the Assessment of Negative Symptoms) total and subscales scores in the population of fifty patients with schizophrenia enrolled into the study. D-serine serum level had a strong trend to be lower among female as compared to male patients with schizophrenia. In the context of this finding, the role of gender in the glutamatergic dysfunction associated with schizophrenia deserves further attention.

Key words:
D-serine, NMDA receptor, schizophrenia, excitatory amino acids, glutamatergic neurotransmission.

Sources

1. Andreasen, N. C.: The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiat. Suppl., 7, 1989, pp. 49-58.

2. Bauer, D., Hamacher, K., Bröer, S., Pauleit, D., Palm, C., Zilles, K., Coenen, H. H., Langen, K. J.: Preferred stereoselective brain uptake of D-serine – a modulator of glutamatergic neurotransmission. Nucl. Med. Biol., 32, 2005, 8, pp. 793-797.

3. Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., De Miranda, J., Wolosker, H., Agam, G.: A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr. Res., 90, 2007, 1-3, pp. 41-51.

4. Evins, A. E., Amico, E., Posever, T. A., Toker, R., Goff, D. C.: D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res., 56, 2002, 1-2, pp. 19-23.

5. Goff, D. C., Tsai, G., Manoach, D. S., Coyle, J. T.: A dose-finding trial of D-cycloserine added to neuroleptic for negative symptoms in schizophrenia. Am. J. Psychiat., 152, 1995, pp. 1213-1215.

6. Hashimoto, A., Oka, T.: Free D-aspatate and D-serine in the mammalian brain and periphery. Prog. in Neurobiol., 52, 1997, pp. 325-353.

7. Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S., Hasegawa, H., Imai, K., Iyo, M.: Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiat., 60, 2003, 6, pp. 572-576.

8. Hashimoto, A., Chiba, Y.: Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat. Eur. J. Pharmacol., 495, 2004, 2-3, pp. 153-158.

9. Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindstrom, L. H., Iyo, M.: Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiat., 29m 2005, 5, pp. 767-769.

10. Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., Javitt, D. C.: Placebo-controlled trial of D-cycloserin added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiat., 159, 2002, 3, pp. 480-482.

11. Heresco-Levy, U., Javitt, D. C.: Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophenia: a retrospective analysis. Schizophr. Res., 66, 2004, 2-3, pp. 89-96.

12. Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., Ermilov, M.: D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiat., 57, 2005, 6, pp. 577-585.

13. Javitt, D. C., Zukin, S. R.: Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat,. 148, 1991, pp. 1301-1308.

14. Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco-Levy, U., Lindenmayer, J. P.: Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiat., 151, 1994, pp. 1234-1236.

15. Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A. M., Bark, N., Park, M., Lindenmayer, J. P., Suckow, R., Zukin, S. R.: Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol., 4, 2001, 4, pp. 385-391.

16. Kay, S. R., Fiszbein, A., Opler, L. A.: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 13, 1987, 2, pp. 261-276.

17. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., Heninger, G. R., Bowers, M. B., Charney, D. S.: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat., 51, 1994, pp. 199-214.

18. Krystal, J. H., Pery, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., D´Souza, D. C.: Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiat., 62, 2005, pp. 985-995.

19. Kutlan, D., Presits, P., Molnar-Perl, I.: Behavior and characteristics of amine derivatives obtained with o-phthaldialdehyde/3-mercaptopropionic acid and with o-phthaldialdehyde/N-acetyl-cysteine reagents. J. Chromatogr. A., 949, 2002, pp. 235-248.

20. Lane, H., Chang, Y., Liu, Y., Chiu, Ch., Tsai, G.: Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia. Arch. Gen. Psychiat., 62, 2005, pp. 1196-1204.

21. Matsui, T., Sekiguchi, M., Hashimoto, A., Tomita, U., Nishikawa, T., Wada, K.: Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration J. Neurochem., 65, 1995, pp. 454-458.

22. Oldendorph, W. M.: Brain uptake of radio labeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol., 221, 1971, pp. 1629-1639.

23. Schell, M. J., Molliver, M. E., Snyder, S. H.: D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. USA., 92, 1995, 9, pp. 3948-3952.

24. Schell, M. J., Brady, R. O., Molliver, M. E., Snyder, S. H.: D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J. Neurosci., 17, 1997, pp. 1604-1615.

25. Schell, M. J.: The N-methyl-D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. Phil. Trans. R. Soc. Lond. B., 359, 2004, pp. 943-964.

26. Scolari, M. J., Acosta, G. B.: D-serine: a new word in the glutamatergic neuro-glial language. Amino Acids., 33, 2007, pp. 563-574.

27. Tomiya, M., Fukushima, T., Watanabe, H., Fukami, G., Fujisaki, M., Iyo, M., Hashimoto, K., Mitsuhashi, S., Toyo´oka, T.: Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin. Chim. Act., 380, 2007, pp. 186-190.

28. Tsai, G., Yang, P., Chung, L., Lange, N., Coyle, J. T.: D-serine added to antipsychotics for treatment of schizophrenia. Biol. Psychiat., 44, 1998, 11, pp. 1081-1089.

29. Tsai, G., Yang, P., Chung, L., Tsai, I., Tsai, Ch., Coyle, J. T.: D-serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiat., 156, 1999, pp. 1822-1825.

30. Tuominen, H. J., Tiihonen, J., Wahlbeck, K.: Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res., 72, 2005, pp. 225-234.

31. Vasanits, A., Kutlan, D., Sass, P., Molnar-Perl, I.: Retention/quantification properties of the o-phthaldialdehyde-3-mercaptopropionic acid and the o-phthaldialdehyde-N-acetyl-L-cysteine amino acid derivatives in reversed-phase high-performance liquid chromatography. J. Chromatogr. A., 870, 2000, pp. 271-287.

32. Wolosker, H., Blackshaw, S., Snyder, S. H.: Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl. Acad. Sci.. 96, 1999, pp. 13409-13414.

33. Wolosker, H., Panizzutti, R., De Miranda, J.: Neurobiology through the looking-glass: D-serine s a new glial-derived transmitter. Neurochem. Internat., 41, 2002, 5, pp. 327-332.

34. Yamada, K., Ohnishi, T., Hashimoto, K., Ohba, H., Iwayama-Shigeno, Y., Toyoshima, M., Okuno, A., Takao, H., Toyota, T., Minabe, Y., Nakamura, K., Shimizu, E., Itokawa, M., Mori, N., Iyo, M., Yoshikawa, T.: Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol. Psychiat., 57, 2005, pp. 1493-1503.

35. Yamamoto, N., Tomita, U., Umino, A., Nishikawa, T.: Uptake of D-serine by synaptosomal P2 fraction isolated from rat brain. Synapse, 42, 2001, 2, pp. 84-86.

36. Zhao, M., Bada, J. L.: Determination of α-dialkylamino acids and their enantiomers in geological samples by high-performance liquid chromatography after derivatization with chiral adduct of o-phthaldialdehyde. J. Chromatogr. A., 690, 1995, pp. 55-63.

Labels

Addictology Paediatric psychiatry Psychiatry

Dissociation and Cognitive Function in Obsessive-compulsive Disorder – cross-sectional study

Cannabinoids and Mental Disorders

Making Clinical Trials Relevant to Clinical Practice: NNT Can Help

Psychiatric Patient and Work Performance

Article was published in

Czech and Slovak Psychiatry

2008 Issue 6